Objectives: To test CIDP patients for IgG positivity towards NF140 and NF155.
Samples: NF140:
| Id (CIDP Holland) | ICQ Id | NF140 IgG Result |
|---|---|---|
| 26 | 18-717 | - |
| 75 | 18-766 | - |
| 76 | 18-767 | - |
| 77 | 18-768 | - |
| 79 (1/40) | 18-770 | - |
| 80 (1/40) | 18-771 | - |
| 85 (1/40) | 18-776 | - |
| 109 (1/40) | 18-800 | - |
| 124 | 18-815 | - |
| 125 | 18-816 | - |
| 126 | 18-817 | - |
| 127 | 18-818 | - |
| 128 | 18-819 | - |
| 129 | 18-820 | - |
| 130 | 18-821 | - |
| 131 | 18-822 | - |
| 132 | 18-823 | - |
| 133 | 18-824 | - |
| 134 | 18-825 | - |
| 135 | 18-826 | - |
| 136 | 18-827 | - |
| 137 | 18-828 | - |
| 138 | 18-829 | - |
| 139 | 18-830 | weak + |
| 140 | 18-831 | - |
| 141 | 18-832 | - |
| 142 | 18-833 | - |
| 143 | 18-834 | - |
| 18-840 | - | |
| Positive Control | 16-069 | + |
| Negative Control | - |
| Id (CIDP Holland) | ICQ Id | NF155 IgG Result |
|---|---|---|
| 45 | 18-736 | - |
| 124 | 18-815 | - |
| 125 | 18-816 | - |
| 126 | 18-817 | - |
| 127 | 18-818 | - |
| 128 | 18-819 | - |
| 129 | 18-820 | - |
| 130 | 18-821 | - |
| 131 | 18-822 | - |
| 132 | 18-823 | - |
| 133 | 18-824 | - |
| 134 | 18-825 | - |
| 135 | 18-826 | - |
| 136 | 18-827 | - |
| 137 | 18-828 | - |
| 138 | 18-829 | - |
| 139 | 18-830 | + |
| 140 | 18-831 | - |
| 141 | 18-832 | - |
| 142 | 18-833 | - |
| 143 | 18-834 | - |
| 18-840 | - | |
| 16-032 | - | |
| Positive control | 17-570 | + |
| Negative control | - |
NF140, NF155 ICC:
- HEKs 293 Cells Transfection: 2018.08.14
- Blocking solution: 5% goat serum in PBS.
- Patient’s sera diluted 1/100 for IgG with 5% goat serum in PBS.
- Primary antibody: AF3235 diluted 1/1000.
- Secondary antibodies: For IgG: GAC 488 (1/1000) + GAH 594 IgG (1/1000)
- Vectashield mounting medium.
RESULTS: Sample 139 is positive for IgG towards NF155. Also is weak positive for IgG towards NF140 and NF186.
